Trials / Completed
CompletedNCT00761709
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Alcon Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL-39256 Ophthalmic Suspension, 1% | |
| DRUG | Latanoprost Ophthalmic Solution, 0.005% | |
| DRUG | Vehicle | Inactive ingredients used as a placebo comparator |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2008-09-29
- Last updated
- 2014-07-15
Source: ClinicalTrials.gov record NCT00761709. Inclusion in this directory is not an endorsement.